The scale of the investment at stake is considerable. Robotic surgery systems for joint replacement typically cost around one million pounds in upfront capital expenditure, with an additional estimated one thousand to two thousand five hundred pounds per patient in procedural costs. For a health service performing hundreds of thousands of hip and knee replacements each year, the difference between adopting robotics widely and continuing with conventional techniques represents a financial commitment running into billions of pounds. Against that backdrop, the researchers behind the new studies argue that their results highlight the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved compared with established surgical methods.

Robotic-assisted joint replacement involves surgeons using computer-controlled robotic arms and high-definition camera systems to assist them during complex procedures. The technology is designed to help plan and execute bone cuts and implant positioning with a precision that exceeds what can be achieved freehand, and earlier studies have consistently shown that robotic assistance does improve the accuracy of implant placement. Better alignment and positioning have long been considered plausible routes to longer-lasting implants, since malpositioned components can wear unevenly, loosen, or destabilise a joint over time. If more precise surgery translated into fewer failed implants, the economics of robotics could eventually prove favourable even at a high initial price. What has remained unclear, however, is whether that theoretical chain of benefit actually holds in clinical practice.

That uncertainty prompted the National Institute for Health and Care Excellence, the body that advises the NHS on which technologies represent value for money, to call for urgent research into the effect of robotic surgery on revision risk after joint replacement. Revision surgery, in which a failed or problematic implant is replaced with a new one, is more complex, more costly, and generally associated with worse outcomes for patients than the original operation. Any technology that reliably reduced revision rates would therefore carry substantial clinical and economic value. The new studies were designed to answer precisely this question using the most comprehensive source of joint replacement data available in the United Kingdom.

The research team analysed National Joint Registry records covering 666,283 total hip replacements, of which 656,080 were performed conventionally and 10,203 robotically, and 697,145 total or partial knee replacements, of which 675,034 were conventional and 22,111 robotic. All procedures took place between 2018 and 2024 in both public and private hospitals across the UK, making this the first big data study of robotic joint replacement conducted in the country. Because patients are not randomly assigned to robotic or conventional surgery, the researchers used a statistical technique known as propensity score matching to balance out underlying differences between the two groups, allowing more reliable comparisons to be drawn from observational data.

Propensity score matching works by pairing patients who underwent robotic surgery with statistically comparable patients who had conventional operations, matching on characteristics that could independently influence outcomes. In this analysis, the factors taken into account included age, sex, body mass index, underlying diagnosis, physical fitness, implant type, and surgeon volume. By constructing balanced comparison groups in this way, the method seeks to mimic the conditions of a randomised controlled trial, an approach known as target trial emulation. The researchers note that this is one of the most robust methods available for analysing observational data, providing vital insights to help commissioners plan care when randomised evidence is not yet available.

Having constructed their matched cohorts, the researchers compared a broad range of outcomes between the robotic and conventional groups, including implant survival, patient survival, the specific reasons for revision surgery, and complications occurring during the operations themselves. Patients were followed for an average of two and a half years after surgery. The results were striking in their uniformity: there were no differences in implant survival, no differences in overall or cause-specific revision risk, and no differences in intraoperative complications between the robotic and conventional hip replacement groups, and the same pattern held for knee replacements. Nor was there any difference in patient survival between the conventional and robotic hip replacement cohorts.

There was one notable exception to the otherwise null findings. Robotic surgery was associated with a lower risk of hip revisions that may be related to implant malpositioning than conventional surgery. This result is consistent with the established finding that robotic systems improve the accuracy of component placement, and it suggests that the technology may indeed reduce the specific subset of failures attributable to imperfect positioning. However, because malpositioning accounts for only a fraction of all revision procedures, this advantage was not large enough to produce a detectable difference in overall revision rates or implant survival across the matched groups during the follow-up period.

The authors are careful to spell out the limitations of their work. These are observational studies, so no firm conclusions can be drawn about cause and effect, and other unmeasured factors could have influenced the findings despite the rigor of the matching process. The average follow-up of two and a half years is also relatively short in the context of joint implants, which are expected to last fifteen to twenty years or more in many patients, and the researchers acknowledge that this limited follow-up period may mask longer-term outcomes that could yet diverge between the two surgical approaches. Questions about patient functional outcomes, such as pain, mobility, and quality of life after surgery, also remain open, and these will be addressed in due course by the ongoing RACER clinical trials.

Even so, the immediate implications for health policy are difficult to ignore. With the NHS planning a sevenfold expansion of robotic surgery by 2035, the new evidence provides the first large-scale national test of whether that investment is justified by improved outcomes, and the answer so far is that it is not, at least for the endpoints of implant survival, revision risk, and surgical complications. The researchers conclude that the results underscore the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved. Until longer-term data or the RACER trials demonstrate benefits that conventional surgery cannot match, the case for widespread adoption of robotics in hip and knee replacement remains, on this evidence, unproven.

Subject of Research: Comparison of robotic-assisted versus conventional hip and knee replacement surgery using UK National Joint Registry data

Article Title: Robotic surgery offers no clear benefit over conventional joint replacement surgery

Article References: Robotic surgery offers no clear benefit over conventional joint replacement surgery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: robotic surgery, hip replacement, knee replacement, joint replacement, National Joint Registry, The BMJ, NHS, revision surgery, implant survival, propensity score matching, health technology assessment, surgical outcomes

The core of the argument is deceptively simple: the scientific case for the central claims made by these products has not been made. Menstrual tracking apps promise to scientifically analyse personal data to improve health, wellbeing, and performance based on where a user is in her menstrual cycle. A companion practice, known as “cycle syncing,” encourages users to adjust their diet and exercise routines according to menstrual cycle phases. Yet Lee and colleagues argue that neither menstrual tracking nor cycle syncing has been convincingly shown to improve health or other performance measures. In other words, the foundational premise of a multibillion-dollar product category rests on evidence that the authors describe as lacking.

The sports science literature is central to their critique. Cycle syncing content frequently draws on the idea that athletic training should be matched to hormonal fluctuations, with harder sessions scheduled in certain phases and recovery prioritised in others. But decades of sports science research, the authors note, show no overall effect of menstrual cycle phase on performance, injury risk, or health. Where effects have been found, they have been trivial in magnitude and highly individualised, meaning they do not generalise into the phase-based training prescriptions that circulate widely online. Research on phase-based dietary interventions intended to reduce menstrual cycle symptoms or improve performance is similarly inconclusive, highly individualised, or speculative. The physiological variation between individuals, and even within the same individual across cycles, overwhelms the average differences that can be attributed to cycle phase.

There is also a deeper technical problem with the products themselves. Even if menstrual phase did correspond with meaningful fluctuations in health, performance, or vulnerability to injury in individuals, Lee and colleagues explain that simple digital tracking technologies cannot reliably predict such variation. Consumer apps typically rely on self-reported data, such as the start and end dates of bleeding, and infer cycle phases from calendar arithmetic rather than direct hormonal measurement. Unlike clinical tools that measure luteinising hormone, progesterone metabolites, or basal body temperature with validated protocols, most apps produce phase estimates with substantial uncertainty. Presenting those estimates to users as actionable scientific insight, the authors argue, misrepresents what the underlying data can actually support.

Beyond the weak evidence base, the commentary catalogues a set of serious risks that the authors say accompany digital cycle tracking technologies. These include wasted time and labour, as users invest effort in logging data and adjusting their lives around predictions of uncertain validity. They include unwanted surveillance, since menstrual data can reveal intimate information about fertility, pregnancy, and health status. They include risks to health data privacy, an area where consumer health apps in many jurisdictions face weaker regulatory protections than medical devices. And they include a subtler harm: these products may distract from, or even threaten, broader efforts to advance women’s health by redirecting attention and resources toward commercial tools of unproven value.

The authors are unusually direct about the stakes. “These apps have the potential for widespread impact on the wellbeing of women and girls,” they warn, yet the evidence that these digital tools can actually help in the management of menstrual conditions, boost health, and provide insights into exercise and nutritional needs is lacking. That combination, wide reach paired with thin evidence, is what elevates the issue from a niche debate about app design to a public health concern. Menstrual tracking is among the most common health-related uses of smartphone technology, and the audience for cycle syncing content on platforms such as social media skews young, meaning many users encounter these claims before they have the background to evaluate them.

The commentary does not stop at diagnosis; it offers a set of suggestions for addressing the risks. The authors call for strengthening protections for consumer and employee data, a pointed reference to the ways menstrual information collected by apps could be used by employers, insurers, or data brokers. They call for improving user awareness of how data are used, so that people who download a tracking app understand what happens to the intimate information they enter. And they advise clinicians to recommend apps to patients only when those apps meet stringent standards, effectively asking the medical profession to act as a gatekeeper against products that have not demonstrated clinical utility. Taken together, these measures would shift the burden of proof from users and regulators onto the companies making health claims.

Other voices in the field, the authors note, have emphasised the need to regulate misleading marketing and to resist the commercial co-option of feminist activist rhetoric. This critique addresses the way femtech products often frame themselves as empowerment, using the language of bodily autonomy and self-knowledge to sell subscription services. The authors also point to an opportunity in the communication landscape itself: tailoring health communication approaches to the social media environments where users actually encounter cycle syncing content. Meeting misleading narratives about hormones and health on the platforms where they spread, rather than in journals or clinics alone, may help build public trust in more credible sources and counteract inaccurate claims before they harden into beliefs.

The authors conclude that health practitioners, regulators, and the general public must be aware of, and work to address, the risks that these consumer technologies pose to women’s health. The commentary appears in The BMJ, with the article titled “Digital menstrual tracking risks creating more harm than benefit,” and is classified as a commentary or editorial drawing on the authors’ expertise across sports science, women’s health, and research on technology and the body. Its publication reflects a growing willingness among researchers to challenge the evidence base of consumer health products that have scaled faster than the science behind them.

For users, the practical message is one of calibrated scepticism rather than outright prohibition. Tracking one’s cycle for personal awareness is not inherently harmful, and menstrual health remains an under-researched field where better tools could genuinely help. The problem, as Lee and colleagues frame it, is the gap between what the technology can deliver and what its marketing promises: apps that cannot reliably predict hormonal variation are being sold as instruments of optimised performance and health insight. Until the evidence catches up, and until data protections and marketing standards are strengthened, the authors argue that the slick presentation of digital menstrual cycle tracking and the scientifically suspect practice of cycle syncing deserve not enthusiasm but scrutiny, and in some cases resistance.

Subject of Research: Evidence and risks of digital menstrual cycle tracking apps and cycle syncing practices

Article Title: Digital menstrual tracking risks creating more harm than benefit, argue experts

Article References: Digital menstrual tracking risks creating more harm than benefit, argue experts. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menstrual tracking, femtech, cycle syncing, health apps, data privacy, women's health, sports science, The BMJ, digital health, surveillance, misleading marketing, consumer health technology

The mechanics of a prescribing cascade are deceptively simple, which is precisely what makes them so difficult to catch in busy clinical practice. Consider one of the clearest examples highlighted in the study: non-steroidal anti-inflammatory drugs, or NSAIDs, which are among the most widely used medications for pain relief in older populations. NSAIDs are known to raise blood pressure in many patients. When that rise occurs, it can easily be read as the emergence of hypertension, a genuine and serious condition in its own right, leading to a new prescription for antihypertensive medication. What gets lost in that transaction is the causal thread connecting the two drugs. The patient now takes two medications instead of one, carries the side-effect burden of both, and the underlying trigger, the NSAID itself, remains untouched. The cascade, once established, can continue to grow.

Older adults are especially vulnerable to this pattern for reasons that are both biological and structural. Advanced age typically brings multiple chronic conditions, and multiple conditions mean multiple prescribing physicians, multiple pharmacies and, frequently, a long list of concurrent medications. When a new symptom appears in a patient taking ten or twelve drugs, tracing it back to a specific medication started months earlier is a formidable task for even the most diligent clinician. The symptom is more likely to be attributed to aging, to one of the existing diagnoses, or to a genuinely new disease. Dr. Rochon, who holds the Barry J. Goldlist Chair in Aging and Health at Sinai Health and is a professor of medicine at the University of Toronto, emphasized that these sequences of events are common but often missed in clinical practice. Knowing what medications a patient is taking, when each one was started, and for what indication, she noted, is essential for identifying problematic cascades before they compound.

To move the problem from anecdote to evidence, the research team assembled an interdisciplinary, international group of collaborators and leaders in drug prescribing and geriatric medicine research spanning the United States, Belgium, Italy, Israel and Ireland. The Canadian side of the effort included Sinai Health researchers Drs. Vasily Giannakeas, Nathan Stall and Christina Reppas-Rindlisbacher, along with research staff Wei Wu and Joyce Li. Working with Lavina Matai and Zhiyin Li at ICES, Ontario’s health data institute, the team gained access to population-level prescription data covering the province, an unusually powerful foundation for studying how prescribing patterns unfold across millions of patients over time rather than within the confines of a single clinic or hospital.

The analytical framework rested on work the team had completed previously: with the expertise of twelve international panelists specializing in internal medicine, geriatric medicine and clinical pharmacology, the researchers had compiled a list of sixty-five potentially inappropriate prescribing cascades drawn from the medical literature and expert consensus. Each cascade on that list describes a first drug, a second drug prescribed in response to the first drug’s adverse effect, and a plausible biological mechanism linking the two. The Ontario study then subjected all sixty-five candidates to a rigorous population-level test built on three criteria. First, how common was the initial drug in the population? Second, how often was it actually followed by the second drug in real-world prescribing data? Third, how strong was the observed link between the two prescriptions?

That three-part analysis allowed the researchers to distill the field down to the twenty-four potentially inappropriate prescribing cascades that are both most commonly seen in the Ontario population and most likely to cause harm. The list spans a striking range of everyday therapeutics. Beyond the NSAID-to-blood-pressure-medication pathway, the study points to cascades involving statins, iron supplements and other widely dispensed drugs, illustrating that the risk is not confined to exotic or high-alert medications. It is embedded in the routine, well-intentioned prescribing that happens thousands of times a day across the province. Because the analysis was conducted at the level of an entire population rather than a selected cohort, the findings offer some of the strongest evidence yet that prescribing cascades are a systemic issue rather than a collection of individual clinical errors.

For Dr. Rochon, the findings illuminate a gap that opens quietly, one prescription at a time. Her concern, she explained, is that the conversations between prescribers and patients that would reveal these connections are so often missed, leaving both parties unaware that a sequence of events is unfolding and that the events are connected to one another. Closing that gap, the team argues, requires physicians to treat medication history as a living document that deserves attention at every visit, not merely a static list of current drugs. Clinicians need to ask why each medication was started in the first place, when it was initiated, and whether the newest prescription on the list is genuinely treating a new disease or simply patching over the side effect of an older one. That reflective pause, applied consistently, could interrupt a cascade before a second or third drug is ever added.

The findings carry particular weight for mature women, a population that sits at the center of Dr. Rochon’s research program. Women tend to live with more chronic conditions than men over their lifetimes, are prescribed more drug therapies, and experience more adverse drug events. Each additional medication increases the surface area for harm, and each additional condition complicates the diagnostic picture when a new symptom emerges. A woman managing osteoporosis, arthritis, cardiovascular risk factors and other conditions simultaneously faces a heightened probability that a drug’s side effect will be mistaken for a new diagnosis rather than traced back to its source. The study’s population-level lens makes clear that this is not a marginal concern but a structural feature of how care is delivered to older women, and one that deserves targeted attention in prescribing guidelines and clinical education alike.

The research team’s conclusions point toward concrete, technologically feasible next steps. The first involves automated clinical decision support tools embedded directly in electronic prescribing systems. Such tools could flag a potential prescribing cascade in real time, alerting the prescriber at the exact moment a new prescription is about to be added that the patient is already taking a drug known to produce the symptom now being treated. Delivered at the point of care, this kind of automated awareness could transform prescribing cascades from an invisible population-level phenomenon into a visible, actionable warning. The technology required is not speculative; the underlying data linkages and rule-based logic mirror systems already used to flag drug allergies and dangerous interactions.

The second proposed step is organizational rather than technical: optimizing the role of pharmacists as full members of the care team and integrating them more directly into the prescribing process alongside physicians. Pharmacists possess precisely the expertise needed to spot the signature of a prescribing cascade, a new drug whose start date closely follows an older drug with a known adverse-effect profile, and to initiate a medication review before the cascade deepens. Together, the two strategies address the problem from complementary angles, embedding vigilance in both the software that supports prescribing decisions and the professional relationships that surround them. As populations age and polypharmacy becomes the norm rather than the exception, the Ontario study suggests that the question is no longer whether prescribing cascades cause widespread harm, but how quickly health systems can build the safeguards needed to stop them.

Subject of Research: Potentially inappropriate prescribing cascades in older adults identified through population-level analysis of Ontario prescription data

Article Title: Ontario study identifies potentially harmful drug combinations prescribed to older adults

Article References: Ontario study identifies potentially harmful drug combinations prescribed to older adults. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prescribing cascades, older adults, polypharmacy, medication safety, geriatric medicine, NSAIDs, blood pressure, statins, clinical decision support, pharmacists, mature women's health, The BMJ